The Beat

AI at HLTH: When AI Gets to Work Inside Clinical Trials

Episode Summary

Move beyond the hype in this episode as we explore how Agentic AI is actively reshaping clinical research by moving from theoretical concepts to real-world autonomous deployments. Tune in to discover how intelligent agents are accelerating trials today and exactly what this shift means for the future of your work. In this episode, host Sandy Vance is behind the mic with Michelle Longmire, the co-founder and Chief Executive Officer of Medable. Together they dive into what Medable is actually building and why it matters. They break down real examples of trials happening now, the evolving role of Clinical Research Associates, and how ambient and agentic AI are taking on the repetitive work that slows teams down.

Episode Notes

Move beyond the hype in this episode as we explore how Agentic AI is actively reshaping clinical research by moving from theoretical concepts to real-world autonomous deployments. Tune in to discover how intelligent agents are accelerating trials today and exactly what this shift means for the future of your work.

In this episode, host Sandy Vance is behind the mic with Michelle Longmire, the co-founder and Chief Executive Officer of Medable. Together they dive into what Medable is actually building and why it matters. They break down real examples of trials happening now, the evolving role of Clinical Research Associates, and how ambient and agentic AI are taking on the repetitive work that slows teams down. 

In this episode, they talk about:

A Little About Michelle:

As the co-founder and Chief Executive Officer of Medable, Dr. Michelle Longmire is mission-driven to accelerate the development of new therapies for disease. A Stanford-trained physician-scientist, Dr. Longmire witnessed firsthand the critical barriers to drug development – including the time and costs associated with clinical trial participation. She founded Medable to pioneer a new category of clinical trial technologies that remove traditional roadblocks to participation and radically accelerate the research process. Medable is now the industry leader in decentralized and direct-to-patient research, with the ability to serve patients in over 120 languages, 60 countries, and across all therapeutic areas. In addition to having raised over $500M in venture capital and driving Medable to an industry-leading position, Dr. Longmire has received recognition as a leading innovator and businesswoman, including being named as one of the 100 most creative people in business by Fast Company.